Proactive - Interviews for investors

Iofina PLC (AIM:IOF, OTC:IOFNF) CEO Dr Tom Becker talked with Proactive's Stephen Gunnion about the company's record achievements in 2024 and its ambitious growth plans for 2025. Becker detailed the production of over 630 metric tons of iodine last year, including a 13% year-over-year increase. He highlighted that the new IO#10 plant, which reached full capacity in late 2024, will contribute significantly to this year's output.

The company is also making strides with IO#11, set to begin production in Q3 2025, and ongoing discussions for IO#12, signalling further expansion. Becker emphasised strong global iodine demand, with prices climbing above $70 per kilogram, benefiting Iofina's operations.

Despite minor shipping delays pushing sales into 2025, Becker assured investors of continued growth and progress. He also celebrated the company's safety track record, with no lost-time accidents since 2021.

Stay tuned for more updates on Iofina PLC and its plans for the future. Don’t forget to like the video, subscribe to Proactive’s YouTube channel, and enable notifications for future updates!"

#Iofina #IodineProduction #ChemicalIndustry #BusinessGrowth #RecordProduction #IO10Plant #IO11Plant #GlobalDemand #ChemicalSafety #ProactiveInvestors

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive's Stephen Gunnion with an update on the company's pancreatic cancer trials.

The company recently announced preliminary results from its ASCEND phase 2 trial at the ASCO Gastrointestinal Conference. According to Mazzo, data from the randomized, double-blind, placebo-controlled Cohort A group demonstrated promising trends in overall survival and efficacy. He highlighted that four complete responses were observed in the Certepetide group out of 63 patients—a stark contrast to zero in the standard care group. This is particularly significant when compared to other trials, such as NAPOLI-3, which had only one complete response in nearly 400 patients.

Mazzo also discussed Cohort B, which investigates a double-dose regimen of Certepetide to explore pharmacodynamic improvements and optimize treatment efficacy.

In addition, Lisata released preliminary data from its iLSTA trial, which examines combining Certepetide with immunotherapy (Durvalumab) and cytotoxics for pancreatic cancer. Mazzo emphasized increased T-cell tumor penetration and higher partial response rates in early data, suggesting potential for enhanced treatment outcomes.

Catch the full interview to learn more about these breakthroughs. Visit Proactive’s YouTube channel for updates, like this video, subscribe, and enable notifications to stay informed.

#LisataTherapeutics #PancreaticCancer #ClinicalTrials #ASCENDTrial #Certepetide #CancerResearch #Immunotherapy #PharmaNews #BiotechInnovations #ProactiveInvestors

ImmuPharma PLC (AIM:IMM) CEO Tim McCarthy joined Stephen Gunnion in the Proactive studio to discuss the company’s recent groundbreaking developments in autoimmune disease treatment. He highlighted the progress made with their P140 platform, emphasising its potential to address multiple autoimmune diseases and transform patient care.

McCarthy explained, “This is a breakthrough in a lot of different ways,” referencing recent preclinical findings that allow the identification and categorisation of autoimmune diseases, paving the way for personalised medicine. He also noted the significant interest in P140 from major pharmaceutical companies, underlining its potential to deliver effective treatment without adverse effects.

Additionally, McCarthy shared updates from the JP Morgan and Biotech Showcase conferences, where these advancements were presented to key industry players. ImmuPharma’s focus in 2025 includes expanding its partnerships and delivering on its transformative pipeline.

Stay tuned for more updates on ImmuPharma’s innovations in the biotech space. Visit Proactive’s YouTube channel for more videos, and don’t forget to like, subscribe, and turn on notifications for future content.

#ImmuPharma #AutoimmuneDiseases #P140Platform #PersonalizedMedicine #Biotech #TimMcCarthy #PharmaceuticalInnovation #LupusTreatment #CIDP #HealthcareRevolution

Giyani Metals Corp (TSX-V:EMM, OTC:CATPF) CEO Charles FitzRoy joined Proactive's Stephen Gunnion with news that the company has secured a 50-year Special Economic Zone (SEZ) Investor License for its battery-grade manganese (HPMSM) commercial plant site to be built in Botswana.

The award of the SEZ License designates Giyani’s Commercial Plant as a Single Factory Special Economic Zone. The Commercial Plant will be located adjacent to its K.Hill manganese mine site, near Kanye, Botswana.

FitzRoy said securing the SEZ License for its Commercial Plant is a transformative step for Giyani, and an important milestone on its path to becoming a leading producer of battery-grade manganese, particularly as its Demo Plant nears first production.

HeLIX Exploration PLC (AIM:HEX) chairman David Minchin joined Proactive's Stephen Gunnion with news that the company has upgraded its helium reserves and economic estimates for the Rudyard Project, in Montanta, and raised around £5 million through an equity issuance.

The proceeds are earmarked to support spending on a gas processing plant and to progress the Rudyard and Ingomar Dome projects.

Minchin said the decision to move forward with an equity raise comes after a detailed review of the economic model and terms of available debt finance.

Helix announced that consultant Aeon Petroleum Consultants Corp has calculated helium reserves of 355 million cubic feet in the northern dome of the Rudyard Project.

Over a 12.5-year project lifespan, Aeon estimates potential net revenue of $115.2 million and sets an asset valuation an NPV8 valuation of $77.9 million, assuming a helium price of $500 per thousand cubic feet (Mcf).

Ariana Resources PLC (AIM:AAU) managing director Kerim Sener talked with Proactive's Stephen Gunnion about the company’s production results and ongoing projects. Ariana has exceeded production guidance for the eighth consecutive year at its Zenit mining operation in Turkey, delivering nearly 21,000 ounces of gold in 2024. Sener emphasised that the Kiziltepe processing plant continues to perform well despite its age, aided by additional ore from the Tavsan operation.

The company reported gross revenue of $54.70 million, its second-highest ever, bolstered by strong gold and silver prices. Sener noted favourable market conditions, supported by central bank buying and commodity price trends, which he expects to continue into 2025.

Sener also highlighted exploration progress in Zimbabwe, with new assay results being integrated into a forthcoming resource model for the Dokwe project. Meanwhile, drilling in Kosovo's Slivova gold project is helping Ariana complete its earn-in to 51% of the project, with further updates expected soon.

Sener expressed optimism for 2025, stating, "At the moment, we're hitting all our guidance figures and continuing to do well across exploration and development."

For more updates on Ariana Resources, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to our channel, and enable notifications for the latest news.

#ArianaResources #GoldMining #TurkeyMining #ZimbabweExploration #KosovoGold #GoldPrices #GoldRevenue #MiningUpdate #InvestorNews #ProactiveInterviews

Greatland Gold PLC (AIM:GGP, OTC:GRLGF) CEO Shaun Day talked with Proactive's Stephen Gunnion about the company's strong production numbers for December following the completion of the Telfer and Havieron acquisition, consolidating ownership under Greatland. The company delivered 33,000 ounces of gold equivalent in just 27 days.

Day emphasised the robust financial position of Greatland, with $145 million in cash and an undrawn debt facility of $75 million, providing over $220 million in liquidity to support its mine plans and life extensions at Telfer. "One of the positive variances to that due diligence is just the receptiveness and the culture at site to being part of Greatland," said Day.

He outlined key upcoming milestones, including the release of the Telfer JORC resource in Q1, the ASX cross-listing in Q2, and the Havieron feasibility study expected in the second half of the year. With plans for ongoing updates, shareholders can look forward to consistent progress throughout the year.

Visit Proactive’s YouTube channel for more videos. Don’t forget to give this video a like, subscribe to the channel, and enable notifications for future updates.

#GreatlandGold #MiningIndustry #GoldProduction #TelferMine #HavieronProject #ASXListing #MiningNews #GoldInvesting #ShaunDay #ResourceDevelopment

The global oncology drug market, valued at USD 231.56 billion in 2024, is expected to grow to USD 532.91 billion by 2031, driven by demand for targeted therapies, biomarker-based treatments, and immunotherapies.

Several ASX-listed companies are contributing to this innovation:

Arovella Therapeutics Ltd: Developing its invariant Natural Killer T (iNKT) cell therapy platform to treat blood cancers and solid tumours. Lead product ALA-101 uses CAR19-iNKT cells to target the CD19 antigen. The company recently raised $20 million to fund a phase 1 trial for CD19-positive blood cancers.

Race Oncology Ltd: Focused on its lead asset, bisantrene, a small-molecule chemotherapeutic with reduced cardiotoxicity. A reformulated version, RC220, is being developed to meet unmet oncology needs.

Imugene Ltd: Advancing immuno-oncology therapies, including azer-cel, an off-the-shelf CAR T therapy targeting CD19 for blood cancers, B-cell vaccine candidates, and CF33 oncolytic virotherapy, which combines engineered viruses with immunotherapies for solid tumours.

Prescient Therapeutics Ltd: Developing personalised cancer treatments with technologies from institutions like Yale and Oxford. Lead drug PTX-100 has FDA Orphan Drug Designation for T-cell lymphomas. Its OmniCAR and CellPryme platforms enhance CAR-T therapies for improved efficacy and adaptability.

These companies exemplify the growth and innovation occurring within the oncology sector.

#ProactiveInvestors #ASX #OncologyMarket #ASXCompanies #ArovellaTherapeutics #RaceOncology #Imugene #PrescientTherapeutics #CancerResearch #ImmunoOncology #CellTherapy #TargetedTherapies #CAR_T #PersonalisedMedicine #CancerCare #BiotechNews #OncologyInnovation #GlobalHealthcare #ClinicalTrials #FDAApproval #SolidTumours #BloodCancers

Proactive’s Tylah Tully breaks down ‘Just the facts’ of the latest news from Silver Mines Ltd (ASX:SVL).

The company has announced the commencement of drilling at its Elsienora Project, part of the Tuena Gold Project in New South Wales.

Located 80 kilometres south of Orange, the project includes multiple gold and silver prospects.

Historical exploration highlights include: 29 metres @ 1.53 g/t gold from surface, 8 metres @ 3.14 g/t gold from 30 metres, and 21 metres @ 0.89 g/t gold from 207 metres.

Gold mining in the area dates back to the 1860s, with historical production records showing 6,758 ounces of gold from Washington Mine and 2,633 ounces from Victoria Mine.

The initial program includes 2,000–3,000 metres of diamond drilling targeting gold and silver, as well as induced polarisation (IP) surveys and reprocessing of historical data.

The company will also investigate historical workings and underexplored targets within adjoining licence EL8974. Drilling is expected to begin this quarter, pending statutory approvals.

#ProactiveInvestors #SilverMines #ASX #ElsienoraProject #TuenaGoldProject #GoldExploration #SilverExploration #DiamondDrilling #MineralExploration #NSWMining #HistoricMining #ResourceDevelopment #MiningUpdates #ASXStocks #IPSurveys #GeologicalExploration #GoldTargets #SilverTargets #MineralProspects #ExplorationDrilling #MiningNews #JustTheFacts

Proactive’s Tylah Tully breaks down ‘Just the facts’ of the latest news from Maximus Resources Ltd (ASX:MXR, OTC:MXRRF).

Maximus has identified shallow high-grade gold mineralisation at the Eagles Nest deposit, 7 kilometres south of the Wattle Dam Gold Project in Western Australia’s Eastern Goldfields.

Recent reverse circulation (RC) drilling produced significant results, including: 10 metres @ 2.24 g/t gold from 37 metres, including 2 metres @ 2.71 g/t and 3 metres @ 3.88 g/t.

Additional scout drilling along the Eagle’s Nest–Groundlark corridor revealed promising anomalies, such as 1 metre @ 1.12 g/t gold and 8 metres @ 0.76 g/t gold.

The drilling program comprised 11 RC holes to validate historical data and assess shallow mineralisation, while scout drilling targeted untested zones within a 3-kilometre corridor.

Eagles Nest hosts an existing resource of 42,550 ounces at 2.0 g/t gold and remains open at depth and along strike. The shallow, free-milling nature of the mineralisation supports its potential as a low-cost and expedited development opportunity.

Further exploration, including additional drilling and resource modelling, is planned to evaluate the scale and economic potential of the deposit.

#ProactiveInvestors #MaximusResources #ASX #OTC #EaglesNest #GoldExploration #WattleDam #EasternGoldfields #GoldMining #DrillingResults #MineralExploration #ASXStocks #GoldDeposits #WesternAustralia #ExplorationUpdates #MiningNews #ResourceExpansion #HighGradeGold #GoldProspects #SystematicDrilling #LowCostDevelopment #MiningOpportunities #GoldCorridor